Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease

Niamh Woods and Ronan MacLoughlin 1 and Ronan MacLoughlin

1 College of Medicine, Nursing & Health Sciences, National University of Ireland, H91 TK33 Galway, Ireland; n.woods7@nuigalway.ie
2 School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland
3 School of Pharmacy and Pharmaceutical Sciences, Trinity College, D02 PN40 Dublin, Ireland
4 Aerogen Ltd., Galway Business Park, H91 HE94 Galway, Ireland
* Correspondence: rmacloughlin@aerogen.com; Tel.: +353-91540400

Received: 9 August 2020; Accepted: 21 September 2020; Published: 26 September 2020

Abstract: Advanced Therapeutic Medicinal Products (ATMP) are a heterogenous group of investigational medicinal products at the forefront of innovative therapies with direct applicability in respiratory diseases. ATMPs include, but are not limited to, stem cells, their secretome, or extracellular vesicles, and each have shown some potential when delivered topically within the lung. This review focuses on that subset of ATMPs. One key mode of delivery that has enabling potential in ATMP validation is aerosol-mediated delivery. The selection of the most appropriate aerosol generator technology is influenced by several key factors, including formulation, patient type, patient intervention, and healthcare economics. The aerosol-mediated delivery of ATMPs has shown promise for the treatment of both chronic and acute respiratory disease in pre-clinical and clinical trials; however, in order for these ATMP device combinations to translate from the bench through to commercialization, they must meet the requirements set out by the various global regulatory bodies. In this review, we detail the potential for ATMP utility in the lungs and propose the nebulization of ATMPs as a viable route of administration in certain circumstances. Further, we provide insight to the current regulatory guidance for nascent ATMP device combination product development within the EU and US.

Keywords: ATMP; regulatory; aerosol; inhalation; nebulizer; extracellular vesicles; conditioned media; mesenchymal stromal cells; secretome; respiratory disease

1. Introduction

Advancements in science and technology have seen the development of new therapeutic opportunities for the treatment and prevention of high-burden human diseases with unmet medical needs [1]. Advanced therapeutic medical products (ATMP) are at the forefront of innovation and are changing the therapeutic landscape for an array of human diseases [2]. ATMP is a broad term used to group three medicinal product classes intended for human use which encompass somatic cell therapy medicine, gene therapy medicines, and tissue-engineered medicines [3].

The three classes of ATMPs are highly heterogeneous in terms of their origin, type, and use [4]. The definition of each class is established in the relevant regulatory documents which define somatic cell therapy medicines (sCTMPs) as products which contain or are comprised of cells or tissues which have been modified for intended clinical use, or biological products which are transferred from one patient to donor with a different use [5]. Gene therapy medicine products (GTMPs) contain recombinant
nucleic acids which have a therapeutic, prophylactic, or diagnostic effect relevant to the recombinant nucleic acid sequence [5]. Tissue-engineered products consist of engineered cells or tissues and present as having properties for or are used in or administered to humans with the view of regenerating, repairing, or replacing a human tissue. Some ATMPs may contain one or more medical device as an integral component of the medicine; this is defined as a combined ATMP (cATMP) [3,5]. This review will focus solely on somatic cell therapy medicine and its utility in respiratory disease, and details the current regulatory hurdles that need to be addressed in bringing a ATMP device combination product to market.

2. Cellular Therapy

Cellular therapy is a field of medicine which has rapidly progressed from research to clinical trials for many disease states [6]. Cellular therapy is based on the principles of rejuvenation, regeneration, and replacement and is converting the currently used symptomatic treatment to a personalized, curative treatment [7]. The development of cellular therapy over the past couple of decades has seen a variety of different therapies receive approval from regulatory bodies such as the Food and Drug Association (FDA) and the European Medicine Authority (EMA) and are available commercially on the market [8]. The cells used in these therapies are either autologous or allogenic, and although they are usually in a differentiated state the cells still retain their proliferative capacity [9]. For example, Kymriah® is a recently approved FDA and EMA cellular product used in the field of immunotherapy which utilizes autologous T cells reprogrammed using a lentiviral vector to target diffuse large-blood-cell lymphoma. The cells are harvested from a patient, expanded, and modified ex vivo before being re-infused back to the same patient, where the results have been shown to be comparable to those of standard chemotherapy approaches [10].

2.1. Mesenchymal Stromal Cells

Cellular therapies such as stem, progenitor, and stem cell derivates show potential in the regulation of pathogenic mechanisms and the promotion of tissue repair and regeneration [11]. Owing to their “stemness” property, the cells hold great promise for the development of new therapeutic approaches for the treatment of respiratory diseases [12,13]. One cell type, in particular, under intense investigation for its potential utility in the treatment of a variety of human diseases are mesenchymal stromal cells (MSCs). The interest in MSC therapy is largely due to their accessibility from adult tissue, their multilineage differentiation potential, and their diverse mechanism of action through both cryoprotective and paracrine effects, as well as their low immunogenicity [14–16].

There have been many in vitro and preclinical studies demonstrating the potential use of MSCs in the treatment of different respiratory diseases, shown in their ability to reduce the inflammation associated with asthma patients and the regeneration of damaged tissue associated with COPD, for example [17,18]. Despite advancements in our understanding of MSCs and their therapeutic potential, until the results from the ongoing clinical trials using MSCs are released, determining the safety and efficacy of MSC administration for respiratory disease, widespread application cannot be considered.

2.2. The Secretome

The secretome is defined as the set of factors/molecules secreted to the extracellular space. These factors include, among others, soluble proteins, free nucleic acids, lipids, and extracellular vesicles [19]. The pro-regenerative effects and diverse mechanistic effects exerted by MSCs are achieved through the activity of the secretome [15]. Following the revelation that MSCs act through a paracrine mechanism, multipotency was no longer the main factor contributing to their therapeutic use; instead, MSCs were recognized as drug stores, reflected in their ability to secrete a plethora of biological materials [20].

The MSC secretome is made up of a cocktail of bioactive components such as anti-inflammatory factors, nucleic acids, cytokines, growth factors, and extracellular vesicles (EV), which play a significant
role in the regulation of a range of physiological processes, thereby potentially making the MSC secretome a high potential target in exerting a therapeutic effect for the treatment of multiple respiratory diseases [21–23]. The therapeutic effects include immunomodulation and anti-inflammatory activity, tissue repair, pro-angiogenic and antimicrobial activity, and the restoration of the protease/anti-protease activity associated with a variety of respiratory diseases [23].

The secretome is highly dynamic and adapts easily to culture conditions; the components may differ subject to donor characteristics or the microenvironment, and, owing to this, MSCs can be primed or preconditioned in order to condition or tailor the cells for maximum benefit [24,25]. MSCs potential in the treatment of any given disease may differ depending on their source, but this conditioning can be used to influence the phenotype, multilineage potential, and immunomodulating capacity of MSCs, ultimately impacting their therapeutic effect [26–28].

Although MSCs hold promise as a cell-based therapy option due to the wide range of therapeutic effects they exert, pre-clinical and clinical trials have highlighted some associated limitations, such as the high cell count doses required, complex storage requirements, and short shelf lives [19,29].

The MSC secretome offers a cell free therapy which can overcome cell-based therapy limitations [30]. Aside from preparing the cell to obtain a desired effect, the secretome overcomes safety considerations of MSC transplantation, such as tumorgenicity, and bypasses the need to deliver large amounts of cells. Moreover, the multi-component secretome can be stored after conditioning, potentially providing an off-the-shelf product readily accessible for the potential treatment of acute respiratory diseases and associated exacerbations, and can be stored without the use of cryoprotectants for a long period of time without compromising the safety of the product [19,25,31,32].

Owing to these factors, the secretome is at the forefront of research and development and is under investigation in a clinical setting in the form of conditioned media (CM) and EVs such as exosomes [15,33].

2.3. Extracellular Vesicles

The therapeutic effect of stem and progenitor cells is attributable not only to their engraftment capacity or their ability to differentiate at the site of damage but due to the paracrine mechanisms which they exert [34]. It is established that this activity is a result of EVs [23].

EVs are membrane-derived particles surrounded by a phospholipid bilayer that are released by cells. In addition to direct cell-to-cell contact and the secretion of soluble factors, EVs also function as a mechanism of intercellular communication. These vesicles are able to efficiently deliver their parental cell-derived molecular cargo to recipient cells—in this case, the respiratory epithelium, which can result in subsequent structural changes at an RNA, protein, or even phenotypic level. EVs are similar in many ways to liposomes in terms of their physical characteristics, in vivo behavior and fate, cellular interactions, and cargo loading, and are thought to hold significant potential in drug delivery applications [35].

EVs offer a unique, dynamic communication network for cells owing to their ability to transport molecules such as cytokines, proteins, lipids, miRNAs, mRNAs, chemokines, and ncRNAs, altering the functions of the recipient cell [36,37].

There has been great interest in EVs from researchers owing to their potential to be used as drug delivery systems, enhancing the target delivery of drugs and surpassing standard drug delivery methods [38]. The advantages of using EV alternative drug delivery systems have been demonstrated in preclinical models, which have shown a low toxicity; high target efficiency; and the ability to escape degradation, resulting in a slower clearance from the body [39,40].

EVs obtained from cells are classified based on their size and source; exosomes are a type of EV, along with micro vesicles and apoptotic bodies, that are 30–100 nm in diameter and are not only secreted by MSCs but also by other stem cells, such as induced pluripotent stem cells (iPSCs), embryonic stem cells (ESC), hematopoietic stem cells (HSC), and neural stem cells (NSC) [39,41]. Though these types of stem cells are considered to be safe to use as therapeutics, there are some biosafety concerns
associated with their application, such as immune-rejection, tumorigenicity, and the potential for abnormal differentiation [42]. Exosomes are suggested as an alternative to stem cell application and are paid increasing attention in studies due to their ability to mimic the effects and the phenotypes of parental cells without the associated risk factors [22,43,44].

The exosomes obtained from MSCs have the ability to mirror the same functions as the mother cell, promoting the repair and regeneration of tissues and cells and restoration homeostasis [45]. It is reported that MSC-derived exosomes are responsible for the paracrine mechanism of MSCs and deliver a biological effect equal to MSCs themselves [46]. MSC-derived exosomes are suggested to have many advantages in contrast to MSCs in the effect that they have on target cells by acting directly with them; the decreased risk of tumorigenicity and immune rejection; their ability to be maintained in cryostorage for a long period of time due to the presence of the plasma membrane; and the ease at which variable factors can be controlled, such as the concentration, dose, and route of administration [46,47]. These properties indicate their potential safe application for respiratory disease therapies which has already been demonstrated in preclinical models [48,49]. Despite this intriguing potential, EVs are not without their risks, with reported detrimental roles in angiogenesis, immunosuppression, and metastasis [50].

3. Respiratory Diseases

Respiratory diseases are among the most common acute and chronic diseases worldwide which occur in both developed and developing societies and are present in among all age groups [51]. Respiratory diseases arise from different factors, such as the inhalation of toxic agents, harmful lifestyle, infection, or genetic factors [51]. Some of the most common disease affecting the respiratory system include acute respiratory distress syndrome (ARDS); chronic obstructive pulmonary disease (COPD); asthma; sepsis; and the more recently described COVID-19, following infection with the Sars-CoV-2 virus.

3.1. Acute Respiratory Distress Syndrome

ARDS is a debilitating disease of the lungs which has a high mortality rate [52]. ARDS arises from a variety of different etiologies, but its most commonly recognized and fatal cause is the pathogenic infection known as pneumonia [53]. Pathogens such as Escherichia coli, Streptococcus pneumoniae, Klebsiella pneumoniae, and Staphylococcus aureus lead to the development of pneumonia causing inflammation, the infiltration of leukocytes to the airspace, and the impaired oxygenation of the blood [53,54].

The complex pathophysiology and development of ARDS makes it difficult to develop therapies for treatment. Current interventions include ventilation, fluid management, antibiotics, and neuromuscular blockade [55,56].

3.2. Chronic Obstructive Pulmonary Disease (COPD)

COPD is a global healthcare problem that is anticipated to become a growing problem as the population ages and the use of tobacco increases. In 2016 in the US, COPD was the fourth leading cause of death, following heart disease, cancer, and cerebrovascular disease, with a total of 251 million reported cases globally and 3.17 million deaths [57]. The major risk factor associated with COPD is the inhalation of toxic chemicals and gases, which leads to the inflammation of the lungs and airways, causing parenchymal destruction and the destruction of lung tissue known as emphysema [58]. There are currently no medicines available that have demonstrated the ability to inhibit the progressive deterioration associated with the disease. The regular use of inhaled bronchodilators is intended to alleviate symptoms associated with COPD [59].

3.3. Asthma

Asthma is a non-communicable chronic inflammatory disease which presents as a lifelong condition and affects all age groups with different severity throughout the course of the asthma
According to the Global Asthma Report, in 2018 asthma affected 339 million people worldwide and the prevalence is continuing to rise [61]. The disease is made up of heterogeneous phenotypes that present differently in terms of their etiology and pathophysiology, with risk factors including genetics and the environment [60].

Asthma is linked to T helper cell type-2 (Th2) immune responses and may be triggered by allergen stimuli factors such as dust mites and pollen, and perennial allergens such as viral infections, cold air, and exercise. These factors can induce a series of events which leads to chronic airway inflammation [62,63]. Elevated levels of Th2 cells in the airways release specific cytokines leading to bronchospasm, an increase in mucus secretion and edema [64]. Current measures to manage asthma only include pharmacological intervention through the use of inhaled corticosteroids (ICS) [65].

3.4. Sepsis

Sepsis presents a significant problem associated with high morbidity and mortality rates and is one of the leading causes of deaths amongst critically ill patients in non-coronary intensive care units in the US [66]. There are various aberrations that underpin sepsis which involve different organs and systems; one of the most established is an uncontrolled inflammatory response [67,68].

Sepsis occurs due to infection which develops past local tissue and causes a cascade of physiological responses which ultimately lead to organ dysfunction [67]. Respiratory tract infections such as pneumonia are the most common associated infection source, and as respiratory dysfunction develops so do complications such as ARDS [69]. Patients with sepsis experience a loss of hypersensitivity and an inability to clean infection and become predisposed to nosocomial infections [70].

Current treatments to improve the condition include early recognition, antibiotics, lung protection ventilation, and methods to reduce nosocomial infections, however, due to the complex nature of sepsis, there is no standardized approach [71]. Despite advancements in the understanding of the pathophysiology of sepsis, there has been no therapeutic agents approved for its treatment and therefore there is an obvious need for the development of novel therapeutic strategies.

3.5. COVID-19

Severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) has been identified as the agent responsible for the disease Coronavirus disease 2019, also known as COVID-19, which has quickly developed into a global pandemic [72,73]. On March 11th, 2020, the World Health Organization (WHO) declared the virus a public health emergency two months following the first identified case in Wuhan, China. COVID-19 primarily targets the lungs [74]. Under normal conditions, the lungs are protected by infiltrating inflammatory cytokines such as macrophages, however this defence system can become over-stimulated in response to harmful agents, resulting in an uncontrolled inflammatory response and causing severe damage to lung tissue [75]. The hyper response known as a “cytokine storm” is central to the progression of COVID-19 and is supported by a complex coordinated process. The process involves: (i) the activation of antigen-presenting cells such as macrophages, which alter the appearance of lymphocytes to the virus; (ii) the activation of pro-inflammatory factors caused by viral RNA replication within the host cell; (iii) lymphocyte apoptosis and immune evasion caused by lymphocyte viral invasion [76,77].

At the time of the publication of this review, there is no vaccine or treatment options available for COVID-19, with prevention of infection and supportive care as the current measures in place [78]. Studies are exploring the potential use of antivirals, antibiotics, and agents such as hydroxychloroquine, however these options are single-target agents and, owing to complexity of the disease, a pleiotropic agent is likely required in order to maximize the therapeutic effect across a range of potential therapeutic strategies, which may influence any of antigen-presenting cell activation, viral RNA replication with cells, and lymphocyte apoptosis, for example [79]. The impact COVID-19 has had on both global health and the economy has been immense and will continue to be unless a novel, effective therapeutic is developed. The use of cellular therapies such as MSCs and exosomes holds great promise as
an alternative approach for the treatment of COVID-19, owing to the protective and reparative effects for pulmonary damage and the ability to suppress host antiviral defenses which characterizes COVID-19 [75,79,80].

4. Routes of Administration for the Treatment of Respiratory Diseases

The efficiency of lung treatment depends on a variety of factors, including the route of administration by which the therapeutic is delivered. Various drug delivery systems have been developed to minimize harmful side effects and to maximize the therapeutic effect of the drug used [81] with inhalation therapy as the most commonly used route of administration for the delivery of drugs for the treatment of respiratory disease [82].

Selecting inhalation as the primary administration route allows the direct targeting of drugs to the airways, permitting the rapid absorption of low-dose medication and potentially lowering the incidence of systemic bioavailability [83]. In contrast, intravenous (IV) administration involves the direct injection of drugs to the blood vessels; by doing this, the amount of available drug is affected by gastrointestinal absorption and hepatic first pass effects before it reaches the lung [84]. Additionally, it is thought that there is aggregation or clumping of EVs and MSCs in the injured lung microvasculature, and this carries the risk of mutagenicity and oncogenicity [85].

Inhalation therapy allows a higher local delivery drug concentration at lower doses to the lungs than that achieved by IV administration, potentially making this non-invasive delivery method more economical due to the requirement for a lower dosage of expensive drugs [82].

Overall, the high pulmonary efficacy, rapid onset, and reduced risk of adverse effects achieved by inhalation therapy is superior to that achieved by delivery to systemic circulation through IV or oral administration [86].

The direct targeting of the lungs and rapid onset is achieved through the use of aerosol generating devices, which include, but are not limited to, pressurized metered dose inhalers (pMDI); dry powder inhalers (DPI); soft mist inhalers (SMI); and nebulizers, which are either air-driven jet nebulizers (JN) or the newer closed-circuit vibrating mesh nebulizers (VMN).

4.1. Combination Product Development—Selecting the Delivery Device

Any combination product development is considered a complex undertaking, but a prudent approach to the development of ATMP/device combinations should begin with the screening and selection of the aerosol generator devices from early in the program. The following must be considered as a whole, as it will have a critical bearing on the ultimate choice of device. Some devices will not be suitable for use with the patient or patient intervention, or even the therapeutic itself.

Patient type: the patient may be any of adult, pediatric, or infant. In combination with the disease state, the patient type will have a direct bearing on the breathing parameters (breath per minute, tidal volumes, inhalation to exhalation ratio, peak inspiratory flow rate), which in turn can affect the aerosol dose delivered to the lung [87,88]. The infant lung is considered the most difficult to administer appreciable amounts of therapeutics to, and treatment options may be very limited [89].

Patient interventions during which the ATMP will be administered: these include oxygen supplementation via a mouthpiece or face mask in spontaneously breathing patients, or ventilatory support either through invasive or non-invasive means (full masks, nasal pillows, nasal cannula). Each intervention will have a direct bearing on the lung dose, and in some instances the device may not be suitable for concurrent usage. For example, DPI is not suitable for use during mechanical ventilation or high-flow nasal therapy. Another consideration may be for how long the patient is in receipt of the ATMP therapy. In this instance, continuity of technology is important. If therapy begins prophylactically, and continues through the escalation of the disease, a variety of patient interventions may be encountered. A review of the literature would suggest that nebulizers are the only technology that can be used concurrently across all of these interventions; however, as will discussed below, VMN consistently delivers the largest amount of formulation to the lung across the interventions, and thus
presents an example of how the appropriate selection of delivery device/technology can streamline combination product development and potentially facilitate expanded ATMP prescription throughout the disease course.

Targeted location within the respiratory tract: depending on the intended site of action, the aerosol droplet size will be a key determinant in getting the therapeutic to where it will have greatest impact. Generally, lower droplet sizes penetrate deeper and towards the lung periphery than larger droplet sizes do. In the case of simple bronchodilators, appropriate targeting through the selection of aerosol droplet sizes has been shown to significantly enhance inhaled drug therapy [90]. Patient-related factors such as breath pattern, position, and disease condition are also known to influence aerosol deposition and distribution [88,91–93].

Formulation design: generally, formulations for inhalation are liquid solutions, liquid suspensions or dry powders. Relating to ATMPs, their efficacy will likely be determined by the number of cells or exosomes, as opposed to a mass of therapeutic acting on a milligram per kilogram basis. As such, it is highly unlikely, for example, that stem cells would be administered as a dry powder (via DPI) or in the low, microliter range dose volumes characteristic of pMDI and SMI. That said, spray drying has been shown to be feasible in the case of exosomes, and, if sufficient quantities could be delivered, could be suitable for MSC-derived proteins and peptides [93]. This notwithstanding, nebulizers are likely the most appropriate choice for use in the critical care setting. However, within the nebulizer choices, there are potential technological limitations—e.g., JN preferentially aerosolize the suspension buffer. Stem cells and even exosomes are suspensions, and therefore potentially unsuitable for bespoke commercial combination with a JN for the economic reasons of wastage. However, the use of JN has been reported to be compatible with MSCs [94]. Table 1 summarizes the formulation characteristics of ATMPs and their potential compatibility with the different aerosol generators alone. As mentioned, however, compatibility alone does not necessarily mean that a device is fit for purpose—for example, the patient intervention needs to be considered in the final device selection for the combination product.

Table 1. Summary of Advanced Therapeutic Medicinal Product (ATMP) formulation characteristics and their compatibility with aerosol generators.

| ATMP and Its Formulation Characteristics | Stem Cell | Secretome | Exosome |
|------------------------------------------|-----------|-----------|---------|
| Micro suspension of cells | | | |
| Mixture of suspended exosomes and solubilized proteins and peptides | | | |
| Nano suspension of exosomes | | | |

| Aerosol Generator | Typical Dose | Potential ATMP Compatibility with Aerosol Generator | Supporting References |
|-------------------|--------------|-------------------------------------------------|-----------------------|
| Dry Powder Inhaler (DPI) | 8–40 mg | No | Yes | Yes | [95,96] |
| Pressurized Metered Dose Inhaler (pMDI) | 25 to 100 µL | No | Yes | Yes | [85] |
| Soft Mist Inhaler | 15 µL | Yes | Yes | Yes | [97] |
| Jet Nebulizer (JN) | 2 to 6 mL | Yes | Yes | Yes | [94,98] |
| Vibrating Mesh Nebulizer (VMN) | 0.1 to 50 mL | Yes | Yes | Yes | [99–101] |

Delivered lung dose and ATMP cost: ATMPs are expensive to produce, and the cost of therapy will be high, with currently approved, non-respiratory ATMPs ranging from tens of thousands to more than a million dollars per treatment [102]. Technological limitations again will limit the adoption of JN, considering that they have a relatively poor performance, with residual doses, not available to
the patient, ranging from 1.0 to 1.8 mL. Depending on the nominal dose originally placed in the JN, this may equate to as little as 40% escaping as potentially inhalable aerosol, with 60% of the dose, by volume, retained in the nebulizer never to become available to the patient \[103,104\]. In this instance, if a JN is chosen as the delivery device, there is the potential for more than half of the therapy to never leave the nebulizer, thus effectively doubling the cost of a dose or treatment. VMN, on the other hand, has emitted doses in excess of 95% of the nominal dose, and so immediately minimizes wastage \[105\].

The dose emitted by a device is taken into the breath and inhaled into the lung. The total dose deposited in the lung has been shown to vary massively with device selection. Using JN and VMN as examples again, multiple-fold differences can be seen on the amount of therapy delivered to the lung, which in turn impacts the potential for therapeutic benefit. One Single-photon emission computed tomography (SPECT-CT) comparison of lung deposition in spontaneously breathing adults demonstrated this clearly, with 5.2 ± 1.1% of the nominal dose initially placed in the nebulizer being delivered with a JN versus 34.1 ± 6.0% being delivered with a VMN in the same patient population (a 6.56-fold difference) \[103\].

One commercial consideration should also be ability to supply the technology, or secure supply at the levels required should the ATMP be a success. Simply naming a general purpose, off the shelf device on a label is to be considered a risky strategy on the basis that, in the future, that device may for whatever reason become unavailable. A co-developed combination product will be developed for the specific patient population and disease target in mind. This approach reduces risk on the basis of a known “built in” reliable and reproducible performance, as well as agreed security of the supply of both the ATMP and device. Additionally, another commercial consideration would be whether the manufacture of the device can scale at the required levels, or whether there is sufficient intellectual property coverage for that device.

Finally, caregiver and by-stander safety must be considered. The recent renewed focus on fugitive emissions during respiratory therapy has highlighted the need for several other potential product requirements. Mitigating, preventing, or capturing exhaled medical or therapeutic aerosols or even patient-derived bioaerosol has become a critical requirement. Several recent studies highlight the risks, the differences between devices, and the steps that can be taken to reduce the risk of unintended inhalation of fugitive emissions. Briefly, the guidance is that closed-circuit nebulizer systems, such as vibrating mesh nebulizers, should be used, and open circuit nebulizer systems, such as jet nebulizers that require a break in the patient circuit should be avoided \[106–110\].

4.2. The Feasibility of Aerosol-Mediated ATMP Delivery

As discussed, MSCs have offered great potential for the treatment of respiratory disease, and their safety has been demonstrated in both preclinical and clinical trials. However there are some problems associated with the administration of the cells, such as the potential for the delivery method to adversely affect the therapeutic effect of the cell, or the failure of the cell to home directly to the target organ, leading to off-target effects \[111,112\]. Of note, during our review of the literature, there was yet no record of the use of aerosol-mediated delivery to the lung for systemic or non-lung targeting. The aerosolization of MSCs and their products has been shown to overcome these associated issues \[113\]. One study using a VMN demonstrated the successful delivery of MSC-derived CM for the treatment of ARDS while maintaining its antibacterial properties \[100\]. Moreover, other studies have shown the ability of MSCs to maintain their engraftment potential following nebulization \[99\]. Table 2 lists some of the recent COVID-19 clinical trials that use aerosol-mediated delivery. A recent state of the art review of the application of ATMPs in respiratory disease and the use of aerosol delivery provides a comprehensive listing of active ATMP trials in respiratory disease \[114\].
Table 2. Clinical trials using inhalation as the delivery method for COVID-19 as an exemplar respiratory disease.

| NCT No.     | Title                                                                                      | Enrolled | Intervention                                                                 | Dose                                                                 | Phase  | Status                       |
|-------------|-------------------------------------------------------------------------------------------|----------|------------------------------------------------------------------------------|----------------------------------------------------------------------|--------|------------------------------|
| NCT04276987 | A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose | 30       | Single-group assignment                                                       | MSC derived exosomes 5 Times aerosol inhalations of MSCs-derived exosomes (2.0 × 10^8 nano vesicles/3 mL at Days 1, 2, 3, 4 and 5 | Phase 1 | Not yet recruiting           |
| NCT04389385 | Aerosol Inhalation of the Exosomes Derived From Allogenic COVID-19 T Cell in the Treatment | 60       | Single-group assignment                                                       | Specific T cell-derived exosomes (CSTC-Exo) Aerosol inhalation of CSTC-Exo (2.0 × 10^8 nanovesicles/3 mL at Day 1,2,3,4 and 5, 5 times daily | Phase 1 | Active, not recruiting       |
|             | of Early Stage Novel Coronavirus Pneumonia                                                                                                           |          |                                                                             | Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy as add-on COVID-19 standard care |        |                              |
| NCT04473170 | Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19 (SENTAD-COVID) | 146      | Parallel assessment                                                           | Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy as add-on COVID-19 standard care | Phase 1 | Completed                    |
|             |                                                                                                                                             |          |                                                                             |                                                                       | Phase 2 |                              |
5. Rationale for Aerosol-Mediated Delivery of Cellular Therapies

Owing to the complexity of the respiratory system, following exposure to different damaging elements such as toxic gases, microparticles, and carbon granules, the system can become severely damaged to the point where it may not return to its original state [115]. There has been a significant increase in the prevalence of respiratory diseases such as COPD and asthma, and yet there are no curative treatments available for these conditions [116,117].

As previously discussed, these respiratory diseases occur due to chronic inflammation and emphysema [58,67]. Cellular therapies offer a novel approach for the treatment of these diseases owing to their anti-inflammatory, anti-fibrotic properties and their ability to repair and replace damaged structures within the lung, such as bronchioles and alveoli, as seen in patients with emphysematous [84,118]. In recent years, the focus of research has been directed towards MSC-based products due to their diverse mechanisms of action [118,119].

In respiratory diseases such as COPD and ARDS in which inflammation plays a fundamental role, the paracrine mechanism, which MSCs exert, modulates the proliferation and activation of immune cells, which themselves are central players in the pathogenesis of both chronic and acute inflammatory lung disease [21,120]. In respiratory disease where lung tissue becomes damaged, MSCs also have the ability to assist lung regeneration by secreting cytokines and growth factors to replace damaged alveolar epithelial cells and restore endothelial permeability [121,122]. Moreover, cellular products such as EVs and CM are under investigation owing to their small size, which means they can be delivered for the treatment of respiratory diseases by non-invasive methods such as inhalation [23].

Importantly, there have been no reported adverse side effects associated with MSC therapy; however, it has been noted that, in parallel with their therapeutic potential, malignant transformation remains a potential risk. The risk is considered highest with embryonic stem cells and induced pluripotent stem cells [123]. As outlined above, aerosol-mediated delivery is possible at all stages throughout the development of the disease, from spontaneous breathing patients (via mouthpiece and facemask), to those in receipt of supplemental oxygen—e.g., via high-flow nasal therapy (via nasal cannula, nose mask) and those patients requiring ventilatory support by either non-invasive or life-sustaining invasive mechanical ventilation (via facemask, hood, tracheostomy tube, endotracheal tube) [124]. The topical administration of aerosolized ATMPs allows for high local concentrations directly at the site of action, as well as the avoidance of the well-documented disadvantages of systemic, gastrointestinal administration. Interestingly, beyond hepatic first losses being a major blockade, for ATMPs it has been proposed that aerosol-mediated delivery helps overcome the risks associated with aggregation in the microvasculature. Considering these factors in combination, aerosol-mediated delivery has the potential to profoundly impact the future of cellular therapies in a clinical setting [23,125,126].

6. Regulatory Framework for ATMP/Device Combination

As with any marketed medicinal product, certain controls during the design and manufacture need to be applied and complied with. Drug device combination products are commonplace, and certainly within the respiratory drug delivery field—for example, dry powder inhalers are specific, co-developed combinations of both a specific drug and a specific device. The same level of development effort and control should be applied to ATMP device combinations in an effort to ensure maximal efficacy and safety.

Within the EU and America, there are an outlined set of legal guidelines in place which oversee the regulation of medicinal products intended for human use, including ATMPs [127,128]. The regulatory framework in place is intended to guarantee the safety, efficacy, and quality of all medicinal products entering the market of each region [128]. The translation of an ATMP from research to clinical trials to product approval is a prolonged process due to not only both scientific and practical obstacles but also regulatory challenges [129]. The development of an ATMP begins with its
6.1. EU Requirements

Regulation plays a crucial part in the translation of novel medicinal products and medical devices from R&D to clinical application, ensuring that all products meet a high quality standard [127]. Within the EU, there is a wide range of legal frameworks in place for medicinal products for human use, which range from products containing chemical substances or biological substances, which include immunological products; products of human origin, such as human plasma; and biotechnological products, such as ATMPs [127].

In the EU, Directive 2001/83/EC and Regulation 726/2004/EC were the regulatory framework structures in place to define a medicinal product intended for human use [128]. These guidelines were revised and, in 2008, new amended regulatory guidelines under Regulation 1394/2007/EC were established specifically for the regulation of ATMPs [3]. The established ATMP regulation outlines regulatory principles for the evaluation, authorization, and post authorization of ATMPs intended for human use so that all member states of the EU follow the standards consistently [112,114]. Regulatory bodies who oversee the regulation of ATMPs include the Committee for Advanced Therapies (CAT) established by the European Medicines Agency (EMA). CAT is a specialized committee responsible for all ATMP-associated activities such as the evaluation of ATMP marketing authorization (MA), assisting scientific developments, as well as offering scientific advice on the classification of ATMPs [128,130].

Before a medicinal product enters the market, an MA is required by competent authorities to guarantee that medicinal products are safe for human use [128]. The Market Authorization Application (MAA) procedure evaluates the quality, safety, and efficacy of all data gathered throughout clinical development, from the proof of concept stage to the human clinical trial stages, ensuring regulatory standards are met [128]. In order to obtain MA approval, the manufacture must comply with the standards set out in both Directive 2001/83/EC and Regulation 726/2004/EC, and the medicinal product must be manufactured in accordance with Good Manufacturing Practices (GMP) guidelines [131].

The end point of the evaluation of data gathered from clinical development is to establish the benefit to risk ratio of the medicinal product; authorization can then only be granted if a positive result is obtained [132]. Due to the human cell-based nature of ATMPs, Directive 2009/120/EC outlines the supplementary clinical and non-clinical data required during the developmental stage [5].

Once safety and efficacy standards are met, in order for ATMPs to reach the market for commercialization a central MA must be secured under the centralized procedure by submitting the MAA to the EMA, which results in product authorization in all EU states and European Economic Area (EEA) regions [128]. There are three different potential routes to be taken for MA, the standard, conditional MA and MA under exceptional circumstances. A standard MA is the most commonly granted MA permitted once a positive benefit risk ratio is demonstrated from generated clinical data [128].

Regarding the regulation of medical devices within the EU, Directive 93/42/EEC on medical devices (MDD) was one of three established key legal frameworks in place that outlined the regulatory standards for the authorization of medical devices [133]. However, the MDD has since been replaced with the Medical Device Regulation (MDR) 2017/745 that requires more in-depth conformity assessments and Clinical Evaluation Reports (CERs), creating a challenging Conformité Européenne (CE) marking process, albeit resulting in the safe and effective medical device released onto the EU market [134]. Of note, due to the COVID-19 pandemic, the MDR will not become fully implemented until 26 May 2021.

Similar to ATMPs, the regulation of medical devices begins with classification early within the development phase [135]. The classification of medical devices is outlined in Annex IX of Directive 93/42/EEC; following these guidelines, the manufacturer must categorizes a device into one or four classes relative to the device characteristics and intended application: Class I, IIa, IIb, and III; see
Table 3 [136]. Nebulizers are the only general purpose, non-paired device on the list of aerosol generators. pMDI, DPI, and SMI are themselves part of a drug–device combination. General-purpose nebulizers are considered Class II.

| Class | Risk    | Description                                                                 | Route                                                                                                                                                      |
|-------|---------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| I     | Low risk| Non-invasive, does not interact with body                                   | Self-declaration route outlines in Annex VII Module. An EU Declaration of Conformity—manufacturer must declare the device satisfies the provisions of the directive. |
| IIa   | Medium  | Generally invasive Therapeutic transfer of energy to patient or used for the diagnosis or monitoring of medical condition | Carry out conformity assessment carried out by NB using Annex II, IV, V, or VI. Can declare conformity with the provisions of directives and regulations (Annex VII). |
| IIb   | Medium  | Invasive—surgical or implantation Potential to modify body fluid            | Full quality assurance (Annex II)—with assessment by NB of technical documents in one sample in accordance with the directive (Annex II, Section 7). |
| III   | High    | Invasive—used to sustain human life, essential to maintain human health Devices connected to CNS or CCS | Full quality assurance system audit (Annex II)—full examination of device by a Notified Body (NB)                                                                 |

Before entering the market, medical devices must be Conformité Européenne (CE)-marked to demonstrate that the device meets the regulatory standards outlined in the MDR and any other relevant EU legislation. Once the device is classified and meets the regulation requirements set forth, the manufacturer must submit an application to a notified body to prove that the device meets the requirements for CE markings [134]. A NB is an organization within the EU appointed to evaluate the conformity of products prior to entering the market [137].

The NB will request certain documentation depending on the device classification and will assess whether the conformity is in compliance with the requirements outlined in the MDR [138]. The manufacturer may be required to implement a quality management system (QMS) in accordance with the MDR (Annex VIII), which includes clinical evaluation, Post Market Surveillance (PMS), and Post Market Clinical Follow-up (PMCF) plans [139]. Moreover, the manufacturer is required to provide CE technical documents that support conformance claims [140]. Following approval, post-market surveillance will be carried out by the relative competent authority to ensure that the safety and effectiveness of medical devices are maintained [138].

6.2. US Requirements

Within the US, the Food and Drug Administration (FDA) is the regulatory body responsible for the approval and authorization of medicines entering the market. The federal food, drug, and cosmetic act (FDCA) and the Public Health Service Act (PHSA) are the two primary statutes which legally authorize the FDA with the responsibility of the regulation of human medicinal products such as biological devices and medical devices [127,141].

Similar to the EU, in the US the regulation of ATMPs follows the same framework as biological products, including allergens, blood products, vaccines, and cell and gene therapy products; the regulatory standards are outlined in Section 351 of the PHSA and under the FDCA [141]. The FDA standards are outlined within the Code of Federal Regulation (CFR), where the regulatory standards for biological and medical devices are outlined under Title 21 of the CFR [141]. There are nine FDA organization centers responsible for product jurisdiction, with the Center for Biologics Evaluation and Research (CBRE) having jurisdiction over biological products, including ATMPs, as well as devices and combination products [141,142].
The 21st Century Cures Act implemented in 2016 was established to assist in the development of ATMPs and saw the establishment of the Regenerative Medicine Advanced Therapy (RMAT) designation developed to assist cellular therapies, tissue-engineered products, and combination products which use biological products as the operating principle [10,143]. According to the act, a drug qualifies for RMAT designation if (I) the drug is a regenerative medicine; (II) the drug’s intended use is for the treatment, modification, reversal or cure of a life-threatening disease or condition; or (III) the drug shows potential to treat diseases or conditions with unmet medical needs based on clinical data [128].

For all medicinal products, including drugs, biologics, and devices, the FDA-outlined good practices (GxPs) must be followed throughout both the manufacturing stage and the release stage, ensuring the safe and effective release of high-quality products. The GxPs include Good Manufacturing Practices (GMP)/Quality System Regulation (QSR), Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and Good Tissue Practice (GTP). The principle of GMP is a basic regulatory requirement to be followed during the manufacturing of drugs and biologics, while QSR would apply to medical devices or the device constituent of a biologic/device combination product [141].

Outlined in Section 3034 of the act are the standards to be followed by the FDA in the evaluation of devices which operate in the recovery, isolation, or delivery of regenerative medicine advanced therapies. The regulatory pathway for devices varies subject to the technical qualities and the intended application of individual devices [144]. The class which the device is categorized into is the primary factor which determines the appropriate pathway to choose for market approval. A device can be classified into one of three groups based on the level of regulation required to assure appropriate safety and effectiveness. The three category groups include: Class I, Class II, and Class III (Table 4) [144].

| Class | Description |
|-------|-------------|
| I     | Devices are subject to a comprehensive set of regulatory authorities called general controls that are applicable to all classes of devices. Devices for which general controls, by themselves, are insufficient to provide reasonable assurance of the safety and effectiveness of the device, and for which there is sufficient information to establish special controls to provide such assurance. |
| II    | Devices for which general controls, by themselves, are insufficient and for which there is insufficient information to establish special controls to provide reasonable assurance of the safety and effectiveness of the device. Class III devices typically require premarket approval. |
| III   | |

Following the classification of the device, there are four premarket pathways available that depend on different characteristics associated with the device: (i) de novo classification request, (ii) premarket approval pathway (PMA), (iii) Humanitarian Device Exemption (HDE), (iv) premarket notification (501 (k)). The latter is the appropriate pathway chosen for a device where a device of the same type has formerly been granted marketing approval and has been recognized as both safe and effective by the FDA [144].

The premarket notification (510 (k)) pathway is chosen when a device is being introduced onto the market for the first time, or when there are modifications made to an existing marketed device which may impact both the safety and capability of the device [144]. Any changes made to the device must be done in compliance with the quality system regulation (21 CFR 820) and documented [145]. The device to be approved must be compared to an alike existing marketed device known as a predicate in order to prove that it is substantially equivalent (SE). In order for the device to be classified as SE, it must demonstrate the same technological features and specified application as the predicate [144].

In the case of a nebulizer, devices which meet the definition of a nebulizer are outlined in 21 CFR 868. A total of 5630 of which are capable of using legal market drug formulations in a way
which is compatible with a labelled formulation and must be evaluated in accordance with device law and regulation [146,147]. For a nebulizer to support substantial equivalence claims, the device must be characterized in vitro and compared to the in vitro data of the predicate device under the Good Laboratory Practice standards [145]. Comparison of the released aerosol from the mouthpiece is a performance characteristic which must be evaluated and includes the total emitted mass, dose delivery uniformity, and particle size distribution [147,148].

However, when a nebulizer is considered a part of a new drug/device combination for the delivery of a new formulation such as cellular products, this requires evaluation by the Center for Drug Evaluation and Research (CDER), as the primary mode of action (PMOA) is the medicinal product. In this case, device performance is evaluated by specialist subcommittees which may be provided by the likes of the Centre for Devices and Radiological Health (CDRH). These performance factors to be evaluated include performance characterization in in vitro and in vivo studies, device safety and efficacy, and clinical study data [131].

7. Conclusions

The aerosol-mediated delivery of ATMPs for the treatment of respiratory disease is under investigation in pre-clinical and clinical studies, and the results obtained from on-going clinical trials will have a significant impact on the future treatment of acute and chronic respiratory diseases. As ATMP/device combination products consist of separate components that are regulated by different health authority divisions, there are many scientific and regulatory challenges which must be overcome before widespread commercial availability. It is vital for manufacturers and regulatory bodies to collaborate and maintain transparency during product development to ensure that products entering the market are at a highly safe and effective standard.

The regulatory roadmap detailed above is intended to serve as a summary guidance to researchers and developers in an effort to streamline the development process. Early-stage researchers can look to de-risk development programs through the early selection of appropriate delivery technologies.

**Author Contributions:** Conceptualization, R.M.; writing—original draft preparation, N.W.; writing—review and editing, N.W. and R.M. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** Ronan MacLoughlin is an employee of Aerogen Limited. Niamh Woods declares no conflicts of interest. Ronan MacLoughlin, of Aerogen Limited, was involved in the writing and revision of the manuscript, as well as the decision to publish. Niamh Woods was responsible for the collection, analysis and interpretation of review findings, as well as the writing and revision of the manuscript.

**References**

1. Scavone, C.; di Mauro, G.; Mascolo, A.; Berrino, L.; Rossi, F.; Capuano, A. The new paradigms in clinical research: From early access programs to the novel therapeutic approaches for unmet medical needs. *Front. Pharmacol.* **2019**, *10*, 111. [CrossRef] [PubMed]
2. Yu, T.T.; Gupta, P.; Ronfard, V.; Vertès, A.A.; Bayon, Y. Recent progress in European advanced therapy medicinal products and beyond. *Front. Bioeng. Biotechnol.* **2018**, *6*, 130. [CrossRef] [PubMed]
3. Regulation, E. No. 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending directive 2001/83/EC and regulation (EC) no 726/2004. *J. Eur. Union* **2007**, *159*, L242/3–12.
4. Flory, E.; Reinhardt, J. European regulatory tools for advanced therapy medicinal products. *Transfus. Med. Hemother.* **2013**, *40*, 409–412. [CrossRef] [PubMed]
5. Commission, E. Editor Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products. *Off. J. Eur. Union* **2009**, *159*, L242/3–12.
6. Zakrzewski, W.; Dobrzyński, M.; Szymonowicz, M.; Rybak, Z. Stem cells: Past, present, and future. *Stem Cell Res. Ther.* 2019, 10, 22. [CrossRef]

7. Nelson, T.J.; Behfar, A.; Terzic, A. Strategies for therapeutic repair: The “R3” regenerative medicine paradigm. *Clin. Transl. Sci.* 2008, 1, 168–171. [CrossRef]

8. Cuende, N.; Rasko, J.E.; Koh, M.B.; Dominici, M.; Ikonomou, L. Cell, tissue and gene products with marketing authorization in 2018 worldwide. *Cytotherapy* 2018, 20, 1401–1413. [CrossRef]

9. Trounson, A. Why Stem Cell Research? *Advances in the Field. Essentials of Stem Cell Biology*; Elsevier: Amsterdam, The Netherlands, 2014; pp. 3–6.

10. U.S. Food and Drug Administration. Regenerative Medicine Advanced Therapy Designation 2019. Available online: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation (accessed on 24 September 2020).

11. Aurora, A.B.; Olson, E.N. Immune modulation of stem cells and regeneration. *Cell Stem Cell* 2014, 15, 14–25. [CrossRef]

12. Till, J.E.; McCulloch, E.A. Hemopoietic stem cell differentiation. *Biochim. Biophys. Acta BBA Rev. Cancer* 1980, 605, 431–459. [CrossRef]

13. Weissman, I.L. Stem cells: Units of development, units of regeneration, and units in evolution. *Cell* 2000, 100, 157–168. [PubMed]

14. Caplan, A. Why are MSCs therapeutic? New data: New insight. *J. Pathol. Soc. G. B. Irel.* 2009, 217, 318–324. [CrossRef] [PubMed]

15. Ferreira, J.R.; Teixeira, G.Q.; Santos, S.G.; Barbosa, M.A.; Almeida-Porada, G.; Gonçalves, R.M. Mesenchymal stromal cell secretome: Influencing therapeutic potential by cellular pre-conditioning. *Front. Immun.* 2018, 9, 2837. [CrossRef]

16. Ayala-Cuellar, A.P.; Kang, J.-H.; Jeung, E.-B.; Choi, K.-C. Roles of mesenchymal stem cells in tissue regeneration and immunomodulation. *Biomed. Ther.* 2019, 27, 25. [CrossRef]

17. Castro, L.L.; Kitoko, J.Z.; Xisto, D.G.; Olsen, P.C.; Guedes, H.L.; Morales, M.M.; Lopes-Pacheco, M.; Cruz, F.F.; Rocco, P.R. Multiple doses of adipose tissue-derived mesenchymal stromal cells induce immunosuppression in experimental asthma. *Stem Cells Transl. Med.* 2020, 9, 250–260. [CrossRef] [PubMed]

18. Cho, J.W.; Park, K.S.; Bae, J.Y. Effects of Wharton’s jelly-derived mesenchymal stem cells on chronic obstructive pulmonary disease. *Regen. Ther.* 2019, 11, 207–211. [CrossRef]

19. Vizoso, F.J.; Eiro, N.; Cid, S.; Schneider, J.; Perez-Fernandez, R. Mesenchymal stem cell secretome: Toward cell-free therapeutic strategies in regenerative medicine. *Int. J. Mol. Sci.* 2017, 18, 1852. [CrossRef]

20. Caplan, A.I. Mesenchymal stem cells: Time to change the name! *Stem Cells Transl. Med.* 2017, 6, 1445–1451. [CrossRef]

21. Harrell, C.R.; Fellabaum, C.; Jovicic, N.; Djonov, V.; Arsenijevic, N.; Volarevic, V. Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome. *Cells* 2019, 8, 467. [CrossRef]

22. Fierabracci, A.; Fattore, A.D.; Muraca, M. The immunoregulatory activity of mesenchymal stem cells: state of art’and ‘future avenues’. *Curr. Med. Chem.* 2016, 23, 3014–3024.

23. Bari, E.; Ferrarotti, I.; Torre, M.L.; Corsico, A.G.; Perteghella, S. Mesenchymal stem/stromal cell secretome for lung regeneration: The long way through “pharmaceuticalization” for the best formulation. *J. Control. Release* 2019, 309, 11–24. [CrossRef] [PubMed]

24. Li, L.; Jin, S.; Zhang, Y. Ischemic preconditioning potentiates the protective effect of mesenchymal stem cells on endotoxin-induced acute lung injury in mice through secretion of exosome. *Int. J. Clin. Exp. Med.* 2015, 8, 3825. [PubMed]

25. Teixeira, F.G.; Salgado, A.J. Mesenchymal stem cells secretome: Current trends and future challenges. *Neural Regen. Res.* 2020, 15, 75. [CrossRef] [PubMed]

26. Najar, M.; Krayem, M.; Merimi, M.; Burny, A.; Meuleman, N.; Bron, D.; Raicevic, L. Insights into inflammatory priming of mesenchymal stromal cells: Functional biological impacts. *Inflamm. Res.* 2018, 67, 467–477. [CrossRef] [PubMed]

27. Hu, C.; Li, L. Preconditioning influences mesenchymal stem cell properties in vitro and in vivo. *J. Cell. Mol. Med.* 2018, 22, 1428–1442. [CrossRef] [PubMed]

28. Zhou, Y.; Tsai, T.-L.; Li, W.-J. Strategies to retain properties of bone marrow-derived mesenchymal stem cells ex vivo. *Ann. N. Y. Acad. Sci.* 2017, 1409, 3. [CrossRef]
29. De Cásia Noronha, N.; Mizukami, A.; Caliário-Oliveira, C.; Cominal, J.G.; Rocha, J.L.M.; Covas, D.T.; Swiec, K.; Malmegrim, K.C.R. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res. Ther. 2019, 10, 131.

30. Abbasi-Malati, Z.; Roushandeh, A.M.; Kuwahara, Y.; Roudkenar, M.H. Mesenchymal stem cells on horizon: A new arsenal of therapeutic agents. Stem Cell Rev. Rep. 2018, 14, 484–499. [CrossRef]

31. Bermudez, M.A.; Sendon-Lago, J.; Seoane, S.; Eiro, N.; Gonzalez, F.; Saa, J.; Vizoso, F.; Perez-Fernandez, R. Anti-inflammatory effect of conditioned medium from human uterine cervical stem cells in uveitis. Exp. Eye Res. 2016, 149, 84–92. [CrossRef]

32. Bermudez, M.A.; Sendon-Lago, J.; Eiro, N.; Trevino, M.; Gonzalez, F.; Yebra–Pimentel, E.; Trevino, M.; Giraldez, M.J.; Macia, M. Corneal epithelial wound healing and bactericidal effect of conditioned medium from human uterine cervical stem cells. Invest. Ophthalmol. Vis. Sci. 2015, 56, 983–992. [CrossRef]

33. Gneccci, M.; Danieli, P.; Malpasso, G.; Ciuffreda, M.C. Paracrine mechanisms of mesenchymal stem cells in tissue repair. In Mesenchymal Stem Cells; Springer: Berlin/Heidelberg, Germany, 2016; pp. 123–146.

34. Barreca, M.M.; Cancemi, P.; Geraci, F. Mesenchymal and Induced Pluripotent Stem Cells-Derived Extracellular Vesicles: The New Frontier for Regenerative Medicine? Cells 2020, 9, 1163. [CrossRef] [PubMed]

35. Van der Meel, R.; Fens, M.H.; Vader, P.; Van Solinge, W.W.; Eniola-Adefeso, O.; Schiela Noronha, N.; Mizukami, A.; Caliário-Oliveira, C.; Cominal, J.G.; Rocha, J.L.M.; Covas, D.T.; Swiec, K.; Malmegrim, K.C.R. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res. Ther. 2019, 10, 131.

36. Simons, M.; Danieli, P.; Malpasso, G.; Ciuffreda, M.C. Paracrine mechanisms of mesenchymal stem cells in tissue repair. In Mesenchymal Stem Cells; Springer: Berlin/Heidelberg, Germany, 2016; pp. 123–146.

37. Barreca, M.M.; Cancemi, P.; Geraci, F. Mesenchymal and Induced Pluripotent Stem Cells-Derived Extracellular Vesicles: The New Frontier for Regenerative Medicine? Cells 2020, 9, 1163. [CrossRef] [PubMed]

38. Lombardo, D.; Kiselev, M.A.; Caccamo, M.T. Smart nanoparticles for drug delivery application: Development of versatile nanocarrier platforms in biotechnology and nanomedicine. J. Nanomater. 2019, 2019, 3702518. [CrossRef] [PubMed]

39. Gangadaran, P.; Ahn, B.-C. Extracellular Vesicle-and Extracellular Vesicle Mimetics-Based Drug Delivery Systems: New Perspectives, Challenges, and Clinical Developments. Pharmaceutics 2020, 12, 442. [CrossRef]

40. Gangadaran, P.; Hong, C.M.; Ahn, B.-C. An update on in vivo imaging of extracellular vesicles as drug delivery vehicles. Front. Pharmacol. 2018, 9, 169. [CrossRef]

41. Han, C.; Sun, X.; Liu, L.; Jiang, H.; Shen, Y.; Xu, X.; Lie, J.; Zhang, G.; Huang, J.; Lin, Z. Exosomes and Their Therapeutic Potentials of Stem Cells. Stem Cells Int. 2016, 7653489. [CrossRef] [PubMed]

42. Mousavinejad, M.; Andrews, P.W.; Shoraki, E.M. Extracellular vesicles as drug delivery systems: Lessons from the liposome field. J. Control. Release 2015, 211, 270–276. [CrossRef] [PubMed]

43. Yaffe, N.; Abeles, R.M.; Eniola-Adefeso, O.; Schiela Noronha, N.; Mizukami, A.; Caliário-Oliveira, C.; Cominal, J.G.; Rocha, J.L.M.; Covas, D.T.; Swiec, K.; Malmegrim, K.C.R. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res. Ther. 2019, 10, 131.

44. Seo, Y.; Kim, H.-S.; Hong, I.-S. Stem cell-derived extracellular vesicles as immunomodulatory therapeutics. Stem Cells Int. 2019, 2019, 3702518. [CrossRef] [PubMed]

45. Lai, R.C.; Yeo, R.W.Y.; Lim, S.K. (Eds.) Mesenchymal stem cell exosomes. In Seminars in Cell & Developmental Biology; Elsevier: Amsterdam, The Netherlands, 2015.

46. Hu, P.; Yang, Q.; Wang, Q.; Shi, C.; Wang, D.; Armato, U.; Prà, L.D.; Chiarini, A. Mesenchymal stem cells-exosomes: A promising cell-free therapeutic tool for wound healing and cutaneous regeneration. Burns Trauma 2019, 7, s41038-019-0178-8. [CrossRef] [PubMed]

47. Mendt, M.; Rezvani, K.; Shpall, E. Mesenchymal stem cell-derived exosomes for clinical use. Bone Marrow Transplant. 2019, 54, 789–792. [CrossRef] [PubMed]

48. Abreu, S.C.; Weiss, D.J.; Rocco, P.R. Extracellular vesicles derived from mesenchymal stromal cells: A therapeutic option in respiratory diseases? Stem Cell Res. Ther. 2016, 7, 53. [CrossRef]

49. Cruz, E.F.; Rocco, P.R. Stem-cell extracellular vesicles and lung repair. Stem Cell Investig. 2017, 4. [CrossRef]

50. Vader, P.; Breakfield, X.O.; Wood, M.J. Extracellular vesicles: Emerging targets for cancer therapy. Trends Mol. Med. 2014, 20, 385–393. [CrossRef]

51. WHO. The Global Impact of Respiratory Disease; World Health Organization: Sheffield, UK, 2017.

52. Force, A.D.T.; Ranieri, V.; Rubenfeld, G.; Thompson, B.; Ferguson, N.; Caldwell, E. Acute respiratory distress syndrome. JAMA 2012, 307, 2526–2533.
53. Tomaszewski, J.J. Pulmonary pathology of the adult respiratory distress syndrome. *Clin. Chest Med.* **1990**, *11*, 593–619.
54. Cukic, V.; Hadzic, A. The most common detected bacteria in sputum of patients with community acquired pneumonia (CAP) treated in hospital. *Med. Arch.* **2016**, *70*, 354. [CrossRef]
55. Silversides, J.A.; Ferguson, N.D. Clinical review: Acute respiratory distress syndrome-clinical ventilator management and adjunct therapy. *Crit. Care* **2013**, *17*, 225. [CrossRef]
56. Papazian, L.; Forel, J.-M.; Gacouin, A.; Fenot-Ragon, C.; Perrin, G.; Loundou, A.; Jaber, S.; Arnal, J.M.; Perez, D.; Seghboyan, J.M. Neuromuscular blockers in early acute respiratory distress syndrome. *N. Engl. J. Med.* **2010**, *363*, 1107–1116. [CrossRef] [PubMed]
57. Xu, J.; Murphy, S.; Kochanek, K.; Arias, E. *Mortality in the United States, 2015*. *NCHS Data Brief, No 267*, US Department of Health and Human Services, CDC, National Center for Health Statistics: Hyattsville, MD, USA, 2016.
58. Barnes, P.J. Small airways in COPD. *N. Engl. J. Med.* **2004**, *350*, 2635–2636. [CrossRef] [PubMed]
59. Devine, J.F. Chronic obstructive pulmonary disease: An overview. *Am. Health Drug Benefits.* **2008**, *1*, 34. [PubMed]
60. Subbarao, P.; Mandhane, P.J.; Sears, M.R. Asthma: Epidemiology, etiology and risk factors. *CmaJ* **2009**, *181*, E181–E90. [CrossRef] [PubMed]
61. Global Asthma Network. The Global Asthma Report 2018. Available online: http://www.globalasthmareport.org/ (accessed on 24 September 2020).
62. Quirt, J.; Hildebrand, K.J.; Mazza, J.; Noya, F.; Kim, H. Asthma. *Allergy Asthma Clin. Immunol.* **2018**, *14*, 50. [CrossRef] [PubMed]
63. Win, P.H.; Hussain, I. Asthma Triggers: What Really Matters? *Clin. Asthma* **2008**, 71–76. [PubMed]
64. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Available online: https://ginaasthma.org/gina-reports/ (accessed on 24 September 2020).
65. O’Byrne, P.; Fabbri, L.M.; Pavord, I.D.; Papi, A.; Petruzzelli, S.; Lange, P. Asthma progression and mortality: The role of inhaled corticosteroids. *Eur. Respir. J.* **2019**, *54*, 1900491. [CrossRef]
66. Angus, D.C.; Linde-Zwirble, W.T.; Lidicker, J.; Clermont, G.; Carcillo, J.; Pinsky, M.R. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. *Crit. Care Med.* **2001**, *29*, 1303–1310. [CrossRef]
67. Delano, M.J.; Ward, P.A. The immune system’s role in sepsis progression, resolution, and long-term outcome. *Immunol. Rev.* **2016**, *274*, 330–353. [CrossRef]
68. Chen, X.-H.; Yin, Y.-J.; Zhang, J.-X. Sepsis and immune response. *World J. Emerg. Med.* **2011**, *2*, 88. [CrossRef]
69. Martin, G.S.; Bernard, G.R. Airway and lung in sepsis. *Intensiv. Care Med.* **2001**, *27*, S63.
70. Denstaedt, S.J.; Singer, B.H.; Standiford, T.J. Sepsis and nosocomial infection: Patient characteristics, mechanisms, and modulation. *Front. Immunol.* **2018**, *9*, 2446. [PubMed]
71. Evans, T. Diagnosis and management of sepsis. *Clin. Med.* **2018**, *18*, 146.
72. Sohrabi, C.; Alsafi, Z.; O’Neill, N.; Khan, M.; Kerwan, A.; Al-Jabir, A.; Iosifidis, C.; Agha, R. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). *Int. J. Surg.* **2020**, *76*, 71–76. [PubMed]
73. Xia, W.; Shao, J.; Guo, Y.; Peng, X.; Li, Z.; Hu, D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. *Pediatric Pulmonol.* **2020**, *55*, 1169–1174.
74. Yuki, K.; Fujiogi, M.; Koutsogiannaki, S. COVID-19 pathophysiology: A review. *Clin. Immunol.* **2020**, 108427.
75. Eiro, N.; Cabrera, J.R.; Fraile, M.; Costa, L.A.; Vizoso, F.J. The Coronavirus Pandemic (SARS-CoV-2): New Problems Demand New Solutions, the Alternative of Mesenchymal (Stem) Stromal Cells. *Front. Cell Dev. Biol.* **2020**, *8*, 645.
76. Liu, Y.; Du, X.; Chen, J.; Jin, Y.; Peng, L.; Wang, H.H.; Lou, M.; Chen, L.; Zhao, Y. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *J. Infect.* **2020**, *81*, e6–e12.
77. Ye, Q.; Wang, B.; Mao, J. Cytokine storm in COVID-19 and treatment. *J. Infect.* **2020**, *80*, 607–613.
78. Centers for Disease Control Prevention. 2020. Available online: https://www.cdc.gov/coronavirus/2019-ncov/therapeutic-options.html (accessed on 24 September 2020).
79. Sengupta, V.; Sengupta, S.; Lazo, A.; Woods, P.; Nolan, A.; Bremer, N. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. *Stem Cells Dev.* **2020**. [CrossRef]
80. Raza, S.S.; Khan, M.A. Mesenchymal Stem Cells: A new front emerge in COVID19 treatment: Mesenchymal Stem Cells therapy for SARS-CoV2 viral infection. *Cytotherapy* **2020.** [CrossRef]

81. Patil, J.; Sarassija, S. Pulmonary drug delivery strategies: A concise, systematic review. *Lung India Off. Organ. Ind. Chest Soc.* **2012**, *29*, 44.

82. Borghardt, J.M.; Kloft, C.; Sharma, A. Inhaled therapy in respiratory disease: The complex interplay of pulmonary kinetic processes. *Can. Respir. J.* **2018**, *2018*, 2732017. [CrossRef] [PubMed]

83. Dolovich, M.B.; Ahrens, R.C.; Hess, D.R.; Anderson, P.; Dhund, R.; Rau, J.L.; Smaldone, G.C.; Guyatt, G. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. *Chest* **2005**, *127*, 335–371. [PubMed]

84. Jin, J.-F.; Zhu, L.-L.; Chen, M.; Xu, H.-M.; Wang, H.-F.; Feng, X.-Q.; Zhu, X.-P.; Zhou, Q. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. *Patient Prefer. Adherence* **2015**, *9*, 923.

85. Clinical trials.gov. A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia 2020. Available online: https://clinicaltrials.gov/ct2/show/NCT04276987?term=exosome%2C+aerosol&cond=Covid19&cntry=CN&draw=2&ranks=1 (accessed on 24 September 2020).

86. Tekade, R.K. *Drug Delivery Systems*; Elsevier Science: Amsterdam, The Netherlands, 2019.

87. Bennett, G.; Joyce, M.; Sweeney, L.; MacLoughlin, R. In vitro study of the effect of breathing pattern on aerosol delivery during high-flow nasal therapy. *Pulm. Ther.* **2019**, *5*, 43–54. [CrossRef]

88. Réminiac, F.; Vecellio, L.; Heuze-Vourch, N.; Petitcollin, A.; Respaud, R.; Cabrera, M.; Pennec, D.L.; Diet, P.; Ehrmann, S. Aerosol therapy in adults receiving high flow nasal cannula oxygen therapy. *J. Aerosol Med. Pulm. Drug Deliv.* **2016**, *29*, 134–141. [CrossRef]

89. MacLoughlin, R.; Telfer, C.; Clark, A.; Fink, J. Aerosol: A novel vehicle for pharmacotherapy in neonates. *Curr. Pharm. Des.* **2017**, *23*, 5928–5934. [CrossRef]

90. Usmani, O.S.; Biddiscombe, M.F.; Barnes, P.J. Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. *Am. J. Respir. Crit. Care Med.* **2005**, *172*, 1497–1504. [CrossRef]

91. Bennett, G.; Joyce, M.; Fernández, E.F.; MacLoughlin, R. Comparison of aerosol delivery across combinations of drug delivery interfaces with and without concurrent high-flow nasal therapy. *Intensive Care Med. Exp.* **2019**, *7*, 20. [CrossRef]

92. Baskin, M.I.; Abd, A.G.; Ilovite, J.S. Regional deposition of aerosolized pentamidine: Effects of body position and breathing pattern. *Ann. Intern. Med.* **1990**, *113*, 677–683. [PubMed]

93. Darquenne, C. Aerosol deposition in health and disease. *J. Aerosol Med. Pulm. Drug Deliv.* **2012**, *25*, 140–147. [PubMed]

94. Averyanov, A.; Konoplyannikov, A.; Zabozlaev, F.; Danilevskaya, O.; Konoplyannikov, M.; Kuzovlev, O.; Kulagina, N.; Koroleva, I. Comparative effects of inhaled and intravenous mesenchymal stem cells in bleomycin-induced pulmonary fibrosis in rabbits. *Eur. Respir. Soc.* **2013**, *42*, 226.

95. Bari, E.; Pefteghella, S.; Di Silvestre, D.; Sorlini, M.; Catenacci, L.; Sorrenti, M.; Marrubini, G.; Rossi, R.; Tripodo, G.; Mauri, P. Pilot production of mesenchymal stem/stromal freeze-dried secretome for cell-free regenerative nanomedicine: A validated GMP-compliant process. *Cells* **2018**, *7*, 190. [CrossRef] [PubMed]

96. Bahr, M.M.; Amer, M.S.; Abo-El-Sooud, K.; Abdallah, A.N.; El-Tookhy, O.S. Preservation techniques of stem cells extracellular vesicles: A gate for manufacturing of clinical grade therapeutic extracellular vesicles and long-term clinical trials. *Int. J. Vet. Sci. Med.* **2020**, *8*, 1–8. [CrossRef]

97. Halim, N.; Ch’ng, E.; Kardia, E.; Ali, S.; Radzi, R.; Yahaya, B. Aerosolised mesenchymal stem cells expressing angiopoietin-1 enhances airway repair. *Stem Cell Rev. Rep.* **2019**, *15*, 112–125. [CrossRef]

98. Dinh, P.-U.C.; Paudel, D.; Brochu, H.; Popowski, K.D.; Gracieux, M.C.; Cores, J.; Huang, K.; Hensley, M.T.; Harrell, E.; Vandergriff, A.C. Inhalation of lung spheroid cells secretome and exosomes promotes lung repair in pulmonary fibrosis. *Nat. Commun.* **2020**, *11*, 1–14. [CrossRef]

99. Kim, S.Y.; Burgess, J.K.; Wang, Y.; Kable, E.P.; Weiss, D.J.; Chan, H.-K.; Chrzanowski, W. Atomized human amniotic mesenchymal stromal cells for direct delivery to the airway for treatment of lung injury. *J. Aerosol Med. Pulm. Drug Deliv.* **2016**, *29*, 514–524. [CrossRef]

100. McCarthy, S.D.; Horgan, E.; Ali, A.; Masterson, C.; Laffey, J.G.; MacLoughlin, R.; O’Toole, D. Nebulized Mesenchymal Stem Cell Derived Conditioned Medium Retains Antibacterial Properties Against Clinical Pathogen Isolates. *J. Aerosol Med. Pulm. Drug Deliv.* **2019**, *33*, 140–152. [CrossRef]
101. Devaney, J.; Chao, J.; Elliman, S.; O’Toole, D.; Laffey, J.G.; MacLoughlin, R. Human Mesenchymal Stromal Cell Derived Exosomes and Conditioned Medium are Nebulisable by Aerogen Vibronic Micropump and Retain Anti-Inflammatory Properties; A34 ARDS AND LUNG INJURY; American Thoracic Society: New York, NY, USA, 2016; p. A1360-A.

102. Seoane-Vazquez, E.; Shukla, V.; Rodriguez-Monguio, R. Innovation and competition in advanced therapy medicinal products. EMBO Mol. Med. 2019, 11, e9992. [CrossRef]

103. Dugernier, J.; Hesse, M.; Vanbever, R.; Depoortere, V.; Roeseler, J.; Michotte, J.-B.; Laterre, P.-F.; Jamar, F.; Rey chler, G. SPECT-CT comparison of lung deposition using a system combining a vibrating-mesh nebulizer with a valved holding chamber and a conventional jet nebulizer: A randomized cross-over study. Pharm. Res. 2017, 34, 290–300. [CrossRef] [PubMed]

104. Reisner, C.; Katial, R.K.; Bartelson, B.B.; Buchmeir, A.; Rosenwasser, L.J.; Nelson, H.S. Characterization of aerosol output from various nebulizer/compressor combinations. Ann. Allergy Asthma Immunol. 2001, 86, 566–574. [CrossRef]

105. Dugernier, J.; Reychler, G.; Wittebole, X.; Roeseler, J.; Depoortere, V.; Sottiaux, T.; Michotte, J.B.; Vanbever, R.; Dugernier, T.; Goffette, P. Aerosol delivery with two ventilation modes during mechanical ventilation: A randomized study. Ann. Intensive Care 2016, 6, 73. [CrossRef] [PubMed]

106. McGrath, J.A.; O’Sullivan, A.; Bennett, G.; O’Toole, C.; Joyce, M.; Byrne, M.A.; MacLoughlin, R. Investigation of the quantity of exhaled aerosols released into the environment during nebulisation. Pharmaceutics 2019, 11, 75. [CrossRef] [PubMed]

107. McGrath, J.A.; O’Toole, C.; Bennett, G.; Joyce, M.; Byrne, M.A.; MacLoughlin, R. Investigation of fugitive aerosols released into the environment during high-flow therapy. Pharmaceutics 2019, 11, 254. [CrossRef]

108. Frank, E.; Ishau, S.; Maier, A.; Reutman, S.; Reichard, J.F. An occupational exposure limit (OEL) approach to protect home healthcare workers exposed to common nebulized drugs. Regul. Toxicol. Pharmacol. 2019, 106, 251–261. [CrossRef]

109. Wilson, J.G.; Liu, K.D.; Zhuo, H.; Caballero, L.; McMillan, M.; Fang, X.; Cosgrove, K.; Vojnik, R.; Calfee, C.S.; Lee, J.-W. Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial. Lancet Respir. Med. 2015, 3, 24–32. [CrossRef]

110. Matthay, M.A.; Calfee, C.S.; Zhuo, H.; Thompson, B.T.; Wilson, J.G.; Levitt, J.E.; Rogers, A.J.; Gotts, J.E.; Wiener-Kronish, J.P.; Bajwa, E.K. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): A randomised phase 2a safety trial. Lancet Respir. Med. 2019, 7, 154–162. [CrossRef]

111. Aver’yanov, A.; Konoplyannikov, A.; Antonov, N.; Osiyeva, G.; Vasil’eva, O.; Sakharova, M.; Tatarskii, A.R.; Kobylyansky, V.I. Survival of Mesenchymal Stem Cells in Different Methods of Nebulization. Bull. Exp. Biol. Med. 2018, 164, 576–578. [CrossRef] [PubMed]

112. Brave, H.; MacLoughlin, R. State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery. Int. J. Mol. Sci. 2020, 21, 6435. [CrossRef] [PubMed]

113. Mason, R.J.; Broaddus, V.C.; Martin, T.R.; King, T.E.; Schraufnagel, D.; Murray, J.E.; Nadel, J.A. Murray and Nadel’s Textbook of Respiratory Medicine E-Book: 2-Volume Set; Elsevier Health Sciences: Amsterdam, The Netherlands, 2010.

114. Cukic, V.; Lovre, V.; Dragisic, D.; Ustamujic, A. Asthma and chronic obstructive pulmonary disease (COPD)–differences and similarities. Mater. Soc. Med. 2012, 24, 100. [CrossRef] [PubMed]

115. Mason, R.J.; Broaddus, V.C.; Martin, T.R.; King, T.E.; Schraufnagel, D.; Murray, J.E.; Nadel, J.A. Murray and Nadel’s Textbook of Respiratory Medicine E-Book: 2-Volume Set; Elsevier Health Sciences: Amsterdam, The Netherlands, 2010.
119. Mohammadipoor, A.; Antebi, B.; Batchinsky, A.I.; Cancio, L.C. Therapeutic potential of products derived from mesenchymal stem/stromal cells in pulmonary disease. *Resp. Res.* 2018, 19, 218. [CrossRef]

120. Cagliani, J.; Grande, D.; Molmenti, E.P.; Miller, E.J.; Rilo, H.L. Immunomodulation by mesenchymal stromal cells and their clinical applications. *J. Stem Cell Regen. Biol.* 2017, 3. [CrossRef]

121. Danchuk, S.; Ylostalo, J.H.; Hossain, F.; Sorge, R.; Ramsey, A.; Bonvillain, R.W.; Lasky, J.A.; Buranel, B.A.; Welsh, D.A.; Prockop, D.J. Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6. *Stem Cell Res. Ther.* 2011, 2, 27. [CrossRef]

122. Wong, A.P.; Keating, A.; Lu, W.-Y.; Duchesneau, P.; Wang, X.; Sacher, A.; Hu, J.; Waddel, T.K. Identification of a bone marrow–derived epithelial-like population capable of repopulating injured mouse airway epithelium. *J. Clin. Investig.* 2009, 119, 336–348. [CrossRef]

123. Prockop, D.J.; Brenner, M.; Fibbe, W.E.; Horwitz, E.; Le Blanc, K.; Phinney, D.G.; Simmons, P.J.; Sensebe, L.; Keating, A. Defining the risks of mesenchymal stromal cell therapy. *Cytotherapy* 2010, 12, 576–578. [CrossRef]

124. Ehrmann, S. Vibrating mesh nebulisers—can greater drug delivery to the airways and lungs improve respiratory outcomes. *Eur. Respir. Pulmon. Dis.* 2018, 4. [CrossRef]

125. McCarthy, S.D.; Gonzalez, H.E.; Higgins, B.D. Future Trends in Nebulized Therapies for Pulmonary Disease. *J. Personal. Med.* 2020, 10, 37. [CrossRef] [PubMed]

126. Gao, J.; Dennis, J.E.; Muzic, R.F.; Lundberg, M.; Caplan, A.I. The dynamic in vivo distribution of bone marrow–derived mesenchymal stem cells after infusion. *Cells Tissues Organs* 2001, 169, 12–20. [CrossRef] [PubMed]

127. Iglesias-Lopez, C.; Agusti, A.; Obach, M.; Vallano, A. Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States. *Front. Pharmacol.* 2019, 10, 766. [CrossRef] [PubMed]

128. Detela, G.; Lodge, A. EU regulatory pathways for ATMPs: Standard, accelerated and adaptive pathways to marketing authorisation. *Mol. Ther. Methods Clin. Dev.* 2019, 13, 205. [CrossRef] [PubMed]

129. Ten Ham, R.M.; Hoekman, J.; Hövels, A.M.; Broekmans, A.W.; Leufkens, H.G.; Klungel, O.H. Challenges in advanced therapy medicinal product development: A survey among companies in Europe. *Mol. Ther. Methods Clin. Dev.* 2018, 11, 121–130. [CrossRef]

130. European Medicines Agency. Committee for advanced therapies (CAT). Available online: https://www.ema.europa.eu/en/committees/committee-advanced-therapies-cat (accessed on 24 September 2020).

131. European Medicines Agency. Guidance on good manufacturing practice and good distribution practice: Questions and answers 2020. Available online: https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-manufacturing-practice/good-distribution-practice-questions-answers (accessed on 24 September 2020).

132. Phillips, L.D. Benefit-Risk Methodology Project. Work Package 1 Report: Description of the Current Practice of Benefit-Risk Assessment for Centralized Procedure Products in the EU Regulatory Network. 2009. Available online: http://eprints.lse.ac.uk/64593/1/Benefit%20risk%20methodology%20project.pdf (accessed on 24 September 2020).

133. French-Mowat, E.; Burnett, J. How are medical devices regulated in the European Union? *J. R. Soc. Med.* 2012, 105, 22–28. [CrossRef]

134. Behan, R.; Watson, M.; Pandit, A. New EU medical device regulations: Impact on the MedTech sector. *Med. Writ.* 2017, 26, 20–24.

135. Purnama, A.; Drago, D. Fundamentals of the European Devices Regulatory Framework. 2019. Available online: https://www.topra.org/TOPRA/TOPRA_MEMBER/PDFs/TOPRA-RR-OCT19-CPD-Supplement.pdf (accessed on 24 September 2020).

136. Directive. C. 93/42/EEC of 14 June 1993 Concerning Medical Devices; OJL Ltd.: Barnsley, UK, 1993.

137. European Commission. Notified Bodies. Available online: https://ec.europa.eu/growth/single-market/goods/building-blocks/notified-bodies_en (accessed on 24 September 2020).

138. Gupta, S.K. Medical Device Regulations: A Current Perspective. *J. Young Pharm.* 2016, 8. [CrossRef]

139. European Commission. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on Medical Devices, Amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and Repealing Council Directives 90/385/EEC and 93/42/EEC; European Commission: Makati, Philippines.
140. UL, EB. Europe Medical Devices Regulation (MDR) CE Marking Regulatory Process 2019. Available online: https://www.emergobyul.com/resources/europe-medical-devices-regulation-mdr-ce-marking-regulatory-process (accessed on 24 September 2020).

141. Mendicino, M.; Fan, Y.; Griffin, D.; Gunter, K.C.; Nichols, K. Current state of US Food and Drug Administration regulation for cellular and gene therapy products: Potential cures on the horizon. Cytotherapy 2019, 21, 699–724. [CrossRef]

142. U.S. Food and Drug Administration. Center for Biologics Evaluation and Research (CBER) 2017. Available online: https://www.fda.gov/about-fda/office-medical-products-and-tobacco/about-center-biologics-evaluation-andresearch-cber (accessed on 24 September 2020).

143. U.S. Food and Drug Administration. 21st Century Cures Act; U.S. Food and Drug Administration: Silver Spring, MD, USA, 2018.

144. U.S. Food and Drug Administration. Evaluation of Devices Used With Regenerative Medicine Advanced Therapies: Guidance for Industry; U.S. Food and Drug Administration: Silver Spring, MD, USA, 2019.

145. Premarket Notification 510 (k). Special Considerations 2020. Available online: https://www.fda.gov/medical-devices/premarket-notification-510k/special-considerations (accessed on 24 September 2020).

146. U.S. Food and Drug Administration. CFR—Code of Federal Regulations Title 21. 2017. Available online: Ecfr.gov/cgi-bin/text-idx (accessed on 24 September 2020).

147. Meyer, R.J. Bringing new nebulizer technologies to market: Regulatory issues. Respir. Care 2002, 47, 1334–1336. [PubMed]

148. De Pablo, E.; Fernández-Garcia, R.; Ballesteros, M.P.; Torrado, J.J.; Serrano, D.R. Nebulised antibiotherapy: Conventional versus nanotechnology-based approaches, is targeting at a nano scale a difficult subject? Ann. Transl. Med. 2017, 5, 448. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).